CA2867418C - Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections - Google Patents

Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections Download PDF

Info

Publication number
CA2867418C
CA2867418C CA2867418A CA2867418A CA2867418C CA 2867418 C CA2867418 C CA 2867418C CA 2867418 A CA2867418 A CA 2867418A CA 2867418 A CA2867418 A CA 2867418A CA 2867418 C CA2867418 C CA 2867418C
Authority
CA
Canada
Prior art keywords
bacteriophage
pharmaceutical composition
strains
seq
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2867418A
Other languages
English (en)
French (fr)
Other versions
CA2867418A1 (en
Inventor
Joao Joao Duarte Alves Mendes
Clara Isabel Rodrigues Leandro
Sofia Volker Corte-Real
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technophage Investigacao e Desenvolvimento em Biotecnologia SA
Original Assignee
Technophage Investigacao e Desenvolvimento em Biotecnologia SA
Tecnifar Industria Tecnica Farmaceutica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technophage Investigacao e Desenvolvimento em Biotecnologia SA, Tecnifar Industria Tecnica Farmaceutica SA filed Critical Technophage Investigacao e Desenvolvimento em Biotecnologia SA
Publication of CA2867418A1 publication Critical patent/CA2867418A1/en
Application granted granted Critical
Publication of CA2867418C publication Critical patent/CA2867418C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3205—Excision instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B2017/320004—Surgical cutting instruments abrasive
    • A61B2017/320008—Scrapers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
CA2867418A 2012-03-19 2013-03-19 Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections Active CA2867418C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612531P 2012-03-19 2012-03-19
US61/612,531 2012-03-19
PCT/PT2013/000016 WO2013141730A1 (en) 2012-03-19 2013-03-19 Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
CA2867418A1 CA2867418A1 (en) 2013-09-26
CA2867418C true CA2867418C (en) 2020-03-10

Family

ID=48534472

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2867418A Active CA2867418C (en) 2012-03-19 2013-03-19 Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections

Country Status (13)

Country Link
US (1) US9962419B2 (enExample)
EP (1) EP2833899B1 (enExample)
JP (1) JP6186427B2 (enExample)
CN (1) CN104519893B (enExample)
AU (1) AU2013235883B2 (enExample)
BR (1) BR112014023321B1 (enExample)
CA (1) CA2867418C (enExample)
DK (1) DK2833899T3 (enExample)
ES (1) ES2814024T3 (enExample)
PT (1) PT2833899T (enExample)
RU (1) RU2654596C2 (enExample)
SG (1) SG11201405829WA (enExample)
WO (1) WO2013141730A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2865383A1 (en) * 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
WO2016066722A2 (en) * 2014-10-28 2016-05-06 Ian Humphery-Smith Bacteriophage combinations for human or animal therapy
US10455983B2 (en) 2015-09-10 2019-10-29 Prince Castle LLC Modular food holding system
US20170157186A1 (en) * 2015-12-02 2017-06-08 Smart Phage, Inc. Phage to treat bacteria on skin
WO2017180862A1 (en) * 2016-04-13 2017-10-19 Northeast Ohio Medical University Gpnmb compositions for treatment of skin wounds
WO2018106135A2 (en) 2016-12-05 2018-06-14 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
JP7370867B2 (ja) 2017-02-13 2023-10-30 アルマタ・ファーマシューティカルズ・インコーポレーテッド 療法バクテリオファージ組成物
US20210065844A1 (en) * 2017-09-05 2021-03-04 Adaptive Phage Therapeutics, Inc. Methods to determine the sensitivity profile of a bacterial strain to a therapeutic composition
MX2020004251A (es) * 2017-10-19 2021-05-27 Mona E Buice Composición tópica para cicatrización mejorada de heridas abiertas.
CA3085314A1 (en) * 2017-12-11 2019-06-20 Adaptive Phage Therapeutics, Inc. Phage dispensing system
JP2021508740A (ja) * 2018-01-02 2021-03-11 アルマタ・ファーマシューティカルズ・インコーポレーテッド Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染症を処置するための治療的バクテリオファージ組成物
CN109082414B (zh) * 2018-06-29 2020-11-13 浙江工业大学 一种金黄色葡萄球菌噬菌体及应用
MX2021000889A (es) 2018-07-24 2021-04-28 Medimmune Llc Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
CN109730235A (zh) * 2019-02-01 2019-05-10 珠海横琴普罗恩能医用食品有限公司 一种用于医用食品的防腐剂
US12576118B2 (en) 2019-05-21 2026-03-17 University of Pittsburgh—of the Commonwealth System of Higher Education Bacteriophages for the treatment of tuberculosis
JP2023523319A (ja) 2020-04-27 2023-06-02 アルマタ・ファーマシューティカルズ・インコーポレーテッド シュードモナス感染症を処置するためのバクテリオファージ組成物
CN111643724B (zh) * 2020-07-01 2022-01-28 南京大学 一种载有噬菌体和酸性成纤维细胞生长因子的水凝胶伤口敷料的制备方法及其应用
WO2022013314A1 (en) 2020-07-14 2022-01-20 Biontech R&D (Austria) Gmbh Bacteriophage cocktails and uses thereof
WO2022013318A1 (en) 2020-07-14 2022-01-20 Biontech R&D (Austria) Gmbh New mosaic bacteriophages and uses thereof
CN112251439B (zh) * 2020-10-26 2022-06-21 齐鲁师范学院 拟南芥高温诱导启动子pHTG1及其重组载体
CN112301001B (zh) * 2020-11-03 2022-10-14 华中农业大学 金黄色葡萄球菌噬菌体lsa2311及其应用
CN113201458B (zh) * 2020-12-21 2022-05-27 青岛诺安百特生物技术有限公司 一种提高噬菌体制剂稳定性的组合物及其应用
AU2022272135A1 (en) * 2021-05-12 2024-01-04 Biomx Ltd. Staphylococcus bacteriophage and uses thereof
WO2022261498A1 (en) * 2021-06-11 2022-12-15 Integrated Pharma Services, Llc Device and methods for acne therapeutics: antibacterial bacteriophages and engineered lysins
DE202022102100U1 (de) 2022-04-20 2022-04-27 Prabhakar Ramesh Bhandari Synergistische antibiotische pharmazeutische Zusammensetzung zur Behandlung von Staphylococcus aureus-Infektionen
EP4626449A1 (en) * 2022-11-28 2025-10-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Acinetobacter baumannii phages
WO2025104708A1 (en) 2023-11-16 2025-05-22 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Method for determining the susceptibility of bacteria to bacteriophages

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU699322B2 (en) 1994-04-05 1998-12-03 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US6138401A (en) 1999-06-25 2000-10-31 Duncan; Franklin R. Fish hook remover
CN1643139A (zh) * 2002-03-25 2005-07-20 沃里克大学 抗菌剂
US20050095222A1 (en) 2003-10-29 2005-05-05 Taro Suzuki Allergen inhibitor, allergen-inhibiting method, allergen-inhibiting fiber and allergen-inhibiting sheet
EP1812025B1 (en) 2004-11-02 2012-09-05 Chr. Hansen A/S Stabilized bacteriophage formulations
MX2007005279A (es) 2004-11-02 2008-03-11 Gangagen Life Sciences Inc Composiciones de bacteriofagos.
CA2593992A1 (en) 2004-12-06 2006-06-15 Rodney M. Donlan Inhibition of biofilm formation using bacteriophage
US20080260697A1 (en) 2005-05-26 2008-10-23 Gangagen Life Sciences Inc. Bacterial Management in Animal Holding Systems
ES2761835T3 (es) * 2009-02-06 2020-05-21 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Fagos antibacterianos, péptidos de fagos y métodos de uso de los mismos
PT104837A (pt) 2009-11-24 2011-05-24 Technophage Investiga O E Desenvolvimento Em Biotecnologia S A P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o
RU2614114C2 (ru) * 2010-09-17 2017-03-22 Текнифар-Индустриа Текника Фармасьютика, С.А Бактериофаги, фаговые пептиды и способы их применения

Also Published As

Publication number Publication date
SG11201405829WA (en) 2014-10-30
BR112014023321A2 (pt) 2022-02-01
DK2833899T3 (da) 2020-09-28
AU2013235883A1 (en) 2014-10-02
CN104519893A (zh) 2015-04-15
RU2654596C2 (ru) 2018-05-21
EP2833899B1 (en) 2020-06-24
WO2013141730A1 (en) 2013-09-26
US9962419B2 (en) 2018-05-08
HK1207002A1 (en) 2016-01-22
EP2833899A1 (en) 2015-02-11
RU2014141941A (ru) 2016-05-20
PT2833899T (pt) 2020-09-15
AU2013235883B2 (en) 2018-01-04
JP6186427B2 (ja) 2017-08-23
CA2867418A1 (en) 2013-09-26
ES2814024T3 (es) 2021-03-25
US20150150919A1 (en) 2015-06-04
BR112014023321B1 (pt) 2022-06-14
JP2015512384A (ja) 2015-04-27
CN104519893B (zh) 2020-02-07

Similar Documents

Publication Publication Date Title
EP2833899B1 (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections.
Bowler et al. Wound microbiology and associated approaches to wound management
US9737579B2 (en) Antibacterial phage, phage peptides and methods of use thereof
EP2283130B1 (en) Dispersin B(TM), 5-fluorouracil, deoxyribonuclease I and proteinase K-based antibiofilm compositions and uses thereof
Aswathanarayan et al. Biofilm-associated infections in chronic wounds and their management
EP1585532A2 (en) Topical anti-infective formulations
US12029766B2 (en) Pharmaceutical composition and methods for the prevention and/or treatment of Staphylococcus aureus using artificial bacterial colonization
WO2020028561A1 (en) Bismuth-thiol compositions and methods for treating wounds
EP4658290A1 (en) Peptides for treatment of skin disease
HK1207002B (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
US9925235B2 (en) Tilapia piscidins for use in enhancement of wound healing
CN1911442B (zh) 一种用于防治创面感染的溶葡萄球菌酶冻干粉剂
Johnson Immune Modulatory and Antimicrobial Properties of Mesenchymal Stromal Cells Delivered Systemically
TW201622741A (zh) 狗圍肛腺瘤之治療方法
Gajakosh Prophylactic Antibiotic and Post Operative Surgical Wound Infection
CN121079309A (zh) 抗细菌肽
Sreejith Effectiveness of Prophylactic Single Dose Antibiotic Versus Multiple Dose Post-Operative Antibiotics in Preventing Surgical Site Infections in Clean and Clean Contaminated Surgeries-A Comparitive Study
TW201536310A (zh) 燒燙傷口癒合組合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180314

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250305

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250305

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250305

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260309

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260309